Plain-English translation of NCT04445285 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called Dornase Alpha (also known as Pulmozyme) can help COVID-19 patients who are having serious trouble breathing. The medication is inhaled directly into the lungs and works by breaking down thick mucus that builds up during severe COVID infection. Researchers want to see if this treatment is safe and if it can improve survival rates over the first 28 days.
COVID-19 can cause severe lung damage and thick mucus buildup that makes it hard or impossible to breathe on your own. This medication has been used safely for other lung conditions, and doctors believe it might help clear the airways and improve survival in the most critically ill COVID patients.
You likely qualify if…
You likely don't qualify if…
If you qualify and agree to join, you will be randomly assigned to receive either the actual medication or a placebo (salt water). You will receive five doses, one per day for five days, through an inhaler or nebulizer (a machine that converts liquid medicine into a mist you breathe in). Researchers will then monitor your health for 28 days to see how you recover and whether the treatment helped.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States
Sponsor
Jon Simmons
Collaborators
University of South Alabama
Enrollment target
~44 participants
Started
April 2020
Primary completion
November 2021
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jon D Simmons, M.D.
Jon Simmons
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.